Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasd ...

Group 1 - Tevogen Bio Holdings Inc. announced that Mittul Mehta, Chief Information Officer, will speak at the Microsoft Fabric Community Conference (FabCon 2026) from March 16–20, 2026, in Atlanta, Georgia [1] - Mr. Mehta will participate in sessions discussing the transformation of data engineering through agentic AI, focusing on adaptive workflows and governance considerations [1][2] - Tevogen.AI aims to apply advanced machine learning to biomedical discovery, including a published international patent application for predicting immunologically active peptides [2] Group 2 - Tevogen is a healthcare enterprise focused on affordability, efficiency, and scientific rigor, leveraging AI and precision T cell therapy to develop life-saving therapies [4] - The company has completed a proof-of-concept clinical trial for its genetically unmodified allogeneic T cells, with a pipeline that includes virology, oncology, and neurology [5] - Tevogen.AI is designed to enhance drug development by accelerating target detection and optimizing clinical trial design through predictive technologies [6] Group 3 - Tevogen is exploring strategic initiatives in domestic generics, biosimilars, medical devices, and innovative insurance solutions to broaden patient access and advance sustainable innovation [7] - The company collaborates with technology leaders like Microsoft and Databricks to support its long-term goals in therapeutic discovery [6]

Core Insights - Tevogen Bio Holdings Inc. is reaffirming its commitment to capital discipline and strategic growth, with a focus on maintaining shareholder value and operational efficiency [13][14]. Capital Management - The company does not anticipate utilizing more than 1% of its total authorized shares over the next twelve months or until it becomes cash-flow positive [2][14]. - Approximately one-fifth of total shares outstanding are in the tradable float, considering the holdings of the lead investor, directors, and named executive officers [2][14]. Shareholder Engagement - The lead investor, Dr. Manmohan Patel, expresses strong confidence in Tevogen's proprietary ExacTcell™ platform and intends to maintain his current shareholdings [2][14]. - The Board of Directors is evaluating the potential declaration of a one-time special cash dividend to shareholders, contingent upon achieving specified financial milestones [4][14]. Growth Strategy - Tevogen is actively evaluating acquisitions that could complement its immunotherapy and artificial intelligence platforms, with the potential to generate over $50 million in combined annual revenue [5][14]. - The company prioritizes a long-term stock-based incentive program aligned with company milestones, focusing on revenue and clinical targets [3][14]. Asset Valuation - Tevogen's intellectual property, proprietary platforms, and strategic partnerships are central to long-term value creation, with independent valuations in 2022 estimating the company at over $4 billion prior to going public [6][14]. - The company is exploring ways to better reflect the value of its assets [6][14]. Product Development - Tevogen Bio has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells, with a pipeline spanning virology, oncology, and neurology [8][14]. - Tevogen.AI aims to transform drug development by accelerating target detection and optimizing clinical trial design through proprietary predictive technologies [9][14]. Future Initiatives - The company is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers [10][14].

Core Insights - Tevogen Bio Holdings Inc. has made significant advancements in its artificial intelligence platform, Tevogen.AI, aimed at improving drug development by identifying effective biological targets before costly clinical trials [1][11]. Database and Data Points - The company has developed a proprietary database containing over 655 million peptide sequences from approximately 24 million proteins, equating to nearly 16 billion data points across various disease areas [2]. Improved Prediction Accuracy - The PredicTcell™ model has shown improved accuracy, with recall increasing from 87% to 92% and precision rising from 40% to 48%, indicating a more effective identification of immune targets [14]. The model is now nearly 20 times more robust than its initial version, trained on 1.8 million data points [3][14]. Continuous Learning and AI Agents - Tevogen.AI operates three production AI agents that create a continuous learning loop between AI predictions and biological validation, enhancing future performance [4]. Partnership Strategy - As predictive accuracy improves, the company plans to explore partnerships with pharmaceutical firms to advance selected peptide candidates for production and development [5]. Long-term Goals - The company aims to reduce trial-and-error in immunotherapy design and enhance success rates while lowering development risks, which could create significant long-term value [6]. Pipeline and Therapeutic Areas - Tevogen Bio's pipeline includes initiatives in virology, oncology, and neurology, utilizing the proprietary ExacTcell™ platform [7]. The company is also exploring future strategic initiatives in domestic generics, biosimilars, medical devices, and innovative insurance solutions [9]. Technological Integration - Tevogen.AI leverages cloud and data services from major technology providers like Microsoft and Databricks to accelerate drug discovery and optimize clinical trial design [8].

Core Insights - Tevogen is advancing the development of TVGN 489, a precision T-cell therapy aimed at addressing Long COVID, coinciding with International Long COVID Awareness Month [1][4] Group 1: Company Developments - Following a new leadership appointment on March 9, 2026, Tevogen is accelerating its "Biotech" and "Digital Health" verticals to progress TVGN 489 into the next clinical phase [2] - The company is evaluating the acquisition of Sciometrix and its Clinicus platform to enhance real-world monitoring for Long COVID patients [2][8] Group 2: Clinical Progress - Tevogen is prioritizing the development of TVGN 489, which targets the estimated 7% of U.S. adults suffering from Long COVID [3] - The proof-of-concept data indicates that none of the patients treated with TVGN 489 for acute infection developed Long COVID [4][6] Group 3: Market Reach and Infrastructure - The expanded HLA coverage of TVGN 489 now reaches 65% of the U.S. population, enhancing its potential patient eligibility [4][12] - The company is finalizing the infrastructure necessary for the next clinical phase based on the proof-of-concept data [12] Group 4: Technological Integration - Tevogen.AI aims to transform drug development by accelerating target detection and optimizing clinical trial design through predictive technologies [7] - The platform utilizes cloud and data services from major technology providers to support therapeutic discovery [7]

Core Viewpoint - Tevogen Bio Holdings Inc. is implementing a diversified growth strategy by appointing interim leaders and evaluating strategic opportunities that could generate over $50 million in annual revenues [1][2] Group 1: Leadership and Strategy - The company has appointed interim leaders across its core business verticals to execute the first phase of its growth strategy [1] - Tevogen is expected to close strategic transactions by the second quarter of 2026, pending due diligence and agreements [2] Group 2: Business Model and Innovations - Tevogen operates as a socially integrated healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing AI and precision T cell therapy [2] - The company’s lead initiative, Tevogen Bio, has completed a proof-of-concept clinical trial for its genetically unmodified allogeneic T cells, with a pipeline that includes virology, oncology, and neurology [3] - Tevogen.AI aims to enhance drug development by improving target detection and clinical trial design through predictive technologies [4] Group 3: Future Initiatives - The company is exploring future strategic initiatives that may encompass domestic generics, biosimilars, medical devices, and innovative insurance solutions [5]

Core Viewpoint - Tevogen Bio Holdings Inc. executed a reverse stock split to meet Nasdaq's minimum bid price requirement, aiming to stabilize its stock value and enhance attractiveness to investors [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split was approved by stockholders on February 19, 2026, allowing the Board to set the final ratio [2]. - The split ratio was set at 50 for 1, converting every 50 shares into one share [2]. - Following the split, the stock trades under the same symbol but with a new CUSIP number, 88165K 200 [3]. Group 2: Stock Performance and Market Data - The current stock price is $6.84, reflecting an 11.74% decrease, equating to a change of $0.91 [3]. - The stock has shown significant volatility, with a daily trading range between $6.22 and $10.76 [4]. - Over the past year, the stock reached a high of $75.50 and a low of $6.22, with a market capitalization of approximately $27.57 million [4]. - The trading volume for the day is reported at 190,619 shares, indicating active trading despite the stock's challenges [4].

Core Viewpoint - Tevogen is focused on evolving into a sustainable, revenue-generating healthcare enterprise through strategic initiatives, including potential acquisitions to enhance its immunotherapy and artificial intelligence platforms [1][2]. Group 1: Strategic Initiatives - The company is actively evaluating potential acquisitions that are expected to operate as subsidiaries, generating positive cash flow and returns on invested capital over time [2][3]. - Preliminary evaluations suggest that the combined entities under consideration may generate aggregate annual revenues exceeding $50 million, aligning with the company's disciplined growth strategy [3]. Group 2: Commitment to Innovation - Tevogen emphasizes that innovation and affordability can coexist, maintaining a commitment to disciplined capital allocation, operational efficiency, and long-term shareholder value creation [4]. - The company aims to develop accessible immunotherapies while strengthening its financial foundation through strategic initiatives [4]. Group 3: Company Overview - Tevogen is a healthcare enterprise built on principles of affordability, efficiency, and scientific rigor, leveraging artificial intelligence and precision T cell therapy platforms [5]. - The company's lead initiative, Tevogen Bio, has completed a proof-of-concept clinical trial demonstrating the potential of its proprietary ExacTcell™ platform across various therapeutic areas [6]. Group 4: Future Directions - Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions, reflecting its mission to advance sustainable innovation and broaden patient access [8].

Core Viewpoint - Tevogen Bio Holdings is pursuing a generics strategy through a potential acquisition of Apozeal Pharmaceutical Inc, aiming to enhance affordability and resilience in the U.S. pharmaceutical supply chain [2][3]. Group 1: Acquisition and Strategy - Tevogen has signed a non-exclusive, non-binding Letter of Intent to explore a transaction with Apozeal, focusing on developing cost-effective medicines [2]. - The potential acquisition could provide Tevogen with established assets and a growing pipeline, including FDA-approved ANDA assets [2]. - CEO Ryan Saadi emphasized that this initiative aligns with the company's mission to support pharmaceutical affordability and domestic manufacturing [3]. Group 2: Financial Performance - Tevogen's stock surged to $10.8 before falling, with shares currently down 15.41% at $6.56, marking a new 52-week low [1][7]. - The company has a market capitalization of $1.56 billion, with institutional ownership at 2.4% [1]. - Over the past 12 months, shares have decreased by 80.44% and are trading significantly below their 20-day and 100-day simple moving averages [4]. Group 3: Technical Analysis - The stock is currently trading 34.5% below its 20-day simple moving average and 58.6% below its 100-day simple moving average, indicating significant weakness [4]. - The RSI is at 21.46, suggesting the stock is in oversold territory, while the MACD shows bearish momentum with a value of -1.4156 [5]. - The combination of an oversold RSI and bearish MACD indicates mixed momentum, suggesting potential for a rebound despite ongoing bearish pressure [5]. Group 4: Market Position - Tevogen's Benzinga Edge scorecard indicates weak momentum (Score: 0.27), highlighting underperformance compared to the broader market [6]. - The company's strategic moves in the generics space could present future opportunities despite current challenges [6].

Core Viewpoint - Tevogen Bio Holdings Inc. is implementing a reverse stock split to address stock price challenges and maintain its Nasdaq listing status [1][2][3] Group 1: Reverse Stock Split Details - The reverse stock split is scheduled for March 6, 2026, with a ratio of 1 share for every 50 shares [1] - The decision was approved by the Board of Directors and aims to meet the Nasdaq Global Market's $1.00 minimum bid price requirement [1][2] - Stockholder approval was granted on February 19, 2026, allowing the Board to finalize the split ratio [1] Group 2: Current Stock Performance - Currently, TVGN's stock is priced at $0.15, reflecting a 16.70% decrease with a change of $0.03 [2] - The stock has fluctuated between $0.14 and $0.18 recently, with a 52-week high of $1.51 and a low of $0.14 [2] Group 3: Market Capitalization and Trading Information - TVGN's market capitalization is approximately $31.3 million, with a trading volume of 2,180,275 shares [3] - After the reverse split, the stock will continue to trade under the symbol "TVGN" but will have a new CUSIP number, 88165K 200 [3] - The reverse split is expected to enhance the stock's appeal to investors by aligning with Nasdaq's listing requirements [3]